The angiotensin-converting enzyme 2 (ACE2) receptor in the prevention and treatment of COVID-19 are distinctly different paradigms

There is current debate concerning the use of angiotensin-converting enzyme (ACE) inhibitors or angiotensin II type 1 receptor blockers (ARBs), for hypertension management, during COVID-19 infection. Specifically, the suggestion has been made that ACE inhibitors or ARBs could theoretically contribut...

Descripción completa

Detalles Bibliográficos
Autor principal: McLachlan, Craig Steven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7360378/
https://www.ncbi.nlm.nih.gov/pubmed/32685191
http://dx.doi.org/10.1186/s40885-020-00147-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7360378/
https://www.ncbi.nlm.nih.gov/pubmed/32685191
http://dx.doi.org/10.1186/s40885-020-00147-x

Ejemplares similares